AR037488A1 - El uso de un compuesto derivado de imidazo (1,2-a) piridina, un compuesto derivado de imidazo (1,2-a) piridina, y un medicamento que contiene dicho compuesto. - Google Patents

El uso de un compuesto derivado de imidazo (1,2-a) piridina, un compuesto derivado de imidazo (1,2-a) piridina, y un medicamento que contiene dicho compuesto.

Info

Publication number
AR037488A1
AR037488A1 ARP020101073A ARP020101073A AR037488A1 AR 037488 A1 AR037488 A1 AR 037488A1 AR P020101073 A ARP020101073 A AR P020101073A AR P020101073 A ARP020101073 A AR P020101073A AR 037488 A1 AR037488 A1 AR 037488A1
Authority
AR
Argentina
Prior art keywords
imidazo
pyridine
phenyl
alkyl
halogen
Prior art date
Application number
ARP020101073A
Other languages
English (en)
Inventor
Vincent Mutel
Jens-Uwe Peters
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR037488A1 publication Critical patent/AR037488A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Uso de un compuesto derivado de imidazo[1,2-a]piridina de fórmula general (1), en la cual: R1 significa hidrógeno, alquilo (C1-6), halógeno, hidroxi, alcoxi (C1-6); R2 significa hidrógeno alquilo (C1-6), halógeno, hidroxi, alcoxi (C1-6); y A significa arilo no sustituido o arilo sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en alquilo(C1-6), halógeno, halógeno-alquilo (C1-6), hidroxi, alcoxi (C1-6), benciloxi, amino, alquilamino, (C1-6), di-alquil-amino (C1-6), arilamino, diarilamino o nitro, o significa heteroarilo no sustituido o heteroarilo sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en alquilo (C1-6), halógeno, halógeno-alquilo (C1-6), hidroxi, alcoxi (C1-6), benciloxi, amino, alquilamino(C1-6), di-alquil-amino(C1-6), arilamino, diarilamino o nitro, o significa el grupo de fórmula (2), en donde: X es, independientemente uno de otro, -CH2- u -O-; y n es 1 ó 2; y sus sales farmacéuticamente aceptables para la elaboración de medicamentos para el tratamiento y la prevención de los trastornos mediados por receptores mGluR5, tales como los trastornos neurológicos agudos y/o crónicos, los trastornos cognitivos y déficits de la memoria tales como enfermedad de Alzheimer, demencia senil, enfermedad de Parkinson, isquemia, corea de Huntington, esclerosis lateral amiotrófica y esclerosis múltiple, enfermedades psiquiátricas tales como psicosis, epilepsia, esquizofrenia, ansiedad y depresión, y el dolor agudo y/o crónico; y un medicamento que contiene uno o más compuestos de fórmula general (1) para el tratamiento y la prevención de trastornos. Un compuesto derivado de imidazo[1,2-a]piridina de fórmula (1) seleccionado entre el grupo que consiste en: 7-cloro-2-(3,4-dimetil-fenil)-imidazo[1,2-a]piridina, 2-(3,4-dimetoxi-fenil)-imidazo[1,2-a]piridina, 2-(3,4-dimetil-fenil)-7-metoxi-imidazo[1,2-a]piridina, 2-(3,4-dimetoxi-fenil)-7-metoxi-imidazo[1,2-a]piridina, 2-(3,4-dimetil-fenil)-7-metil-imidazo[1,2-a]piridina, 2-(3-bromo-4-fluoro-fenil)-imidazo[1,2-a]piridina, 2-(4-benciloxi-3-metoxi-fenil)-imidazo[1,2-a]piridina, 2-indan-5-il-imidazo[1,2-a]piridina, 2-(3-bromo-fenil)-imidazo[1,2-a]piridina, 2-(3-yodo-fenil)-imidazo[1,2-a]piridina, 2-(3-metil-fenil)-imidazo[1,2-a]piridina, 2-benzo[b]tiofen-3-il-imidazo[1,2-a]piridina, 2-(3-trifluorometil-fenil)-imidazo[1,2-a]piridina, 2-(2,3-dihidro-benzofuran-5-il)-imidazo[1,2-a]piridina, 2-(3-fluoro-fenil)-imidazo[1,2-a]piridina, 2-(3,4-dimetil-fenil)-7-etil-imidazo[1,2-a]piridina, 2-(5-metil-tiofen-2-il)-imidazo[1,2-a]piridina, 2-(2,5-dimetil-tiofen-3-il)-imidazo[1,2-a]piridina, o 2-(3,4-dimetoxi-fenil)-6-metil-imidazo[1,2-a]piridina; un medicamento que contiene uno o más de estos compuestos; y estos compuestos, así también como sus sales farmacéuticamente aceptables, para el tratamiento o prevención de enfermedades.
ARP020101073A 2001-03-27 2002-03-25 El uso de un compuesto derivado de imidazo (1,2-a) piridina, un compuesto derivado de imidazo (1,2-a) piridina, y un medicamento que contiene dicho compuesto. AR037488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01107562 2001-03-27

Publications (1)

Publication Number Publication Date
AR037488A1 true AR037488A1 (es) 2004-11-17

Family

ID=8176948

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020101073A AR037488A1 (es) 2001-03-27 2002-03-25 El uso de un compuesto derivado de imidazo (1,2-a) piridina, un compuesto derivado de imidazo (1,2-a) piridina, y un medicamento que contiene dicho compuesto.
ARP070103631A AR062387A2 (es) 2001-03-27 2007-08-16 El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070103631A AR062387A2 (es) 2001-03-27 2007-08-16 El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene

Country Status (17)

Country Link
US (3) US6596731B2 (es)
EP (1) EP1381363B1 (es)
JP (1) JP4088162B2 (es)
KR (1) KR100557847B1 (es)
CN (1) CN1529597A (es)
AR (2) AR037488A1 (es)
AT (1) ATE284214T1 (es)
AU (1) AU2002312768B2 (es)
BR (1) BR0208387A (es)
CA (1) CA2439291C (es)
DE (1) DE60202200T2 (es)
DK (1) DK1381363T3 (es)
ES (1) ES2232756T3 (es)
MX (1) MXPA03008525A (es)
PT (1) PT1381363E (es)
WO (1) WO2002092086A1 (es)
ZA (1) ZA200306341B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
AU2002352443A1 (en) * 2001-12-21 2003-07-15 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
EP1547996A4 (en) * 2002-08-30 2006-08-02 Bf Res Inst Inc DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES HAVING PRION PROTEIN ACCUMULATION AND METHOD OF MARKING
US7105533B2 (en) * 2002-09-13 2006-09-12 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
DE10247271A1 (de) * 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
WO2005060571A2 (en) * 2003-12-10 2005-07-07 Merck & Co., Inc. Antiprotozoal imidazopyridine compounds
SI1756086T1 (sl) 2004-06-01 2008-08-31 Hoffmann La Roche Piridin-4-il-etinil-imidazoli in pirazoli kot antagonisti receptorja mglu5
ATE460417T1 (de) 2005-03-23 2010-03-15 Hoffmann La Roche Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
AU2006298829B2 (en) 2005-09-27 2011-03-03 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
JP2009517469A (ja) * 2005-11-28 2009-04-30 マリンクロッド・インコーポレイテッド イミダゾールピリジンの改良された製造方法
BRPI0706560A2 (pt) * 2006-01-17 2011-03-29 Hoffmann La Roche derivados de aril-isoxazol-4-il-imidazo [1,2-a] piridina úteis para o tratamento de doença de alzheimer por intermédio de receptores gaba
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
TW200808795A (en) 2006-05-19 2008-02-16 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
EP2042501B1 (en) * 2006-06-21 2017-04-12 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
WO2008056481A1 (fr) * 2006-11-09 2008-05-15 Nihon Medi-Physics Co., Ltd. Agent d'imagerie de diagnostic radioactif
CN101535309A (zh) * 2006-11-17 2009-09-16 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
NZ577511A (en) * 2006-11-30 2012-04-27 Nihon Mediphysics Co Ltd 2-Phenyl-imidazo[1,2-a]pyridine derivatives substituted with a radioactive halogen substituent
TWI406674B (zh) 2007-02-13 2013-09-01 Nihon Mediphysics Co Ltd Method for manufacturing diagnostic radiographic diagnostic agents
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EP2180893B1 (en) * 2007-08-09 2014-11-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
JP5433579B2 (ja) 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
CN101903381A (zh) * 2007-10-24 2010-12-01 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物
KR20100101576A (ko) * 2007-10-30 2010-09-17 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
EP2218463A1 (en) * 2007-10-30 2010-08-18 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
CA2704139A1 (en) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Utilization of novel compounds with amyloid affinity and method of producing the same
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
MX2010005110A (es) * 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
PL2280706T3 (pl) * 2008-05-14 2013-05-31 Otsuka Pharma Factory Inc Kompozycje zawierające pochodne benzenu aktywujące lipazę lipoproteinową
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) * 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US10016424B2 (en) 2013-09-16 2018-07-10 INSERM (Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of epilepsy
SI3096790T1 (sl) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne aleostrične modulatorje ali ortosterične agoniste metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
DK3355699T3 (da) * 2015-09-29 2021-06-07 Onco Therapy Science Inc Bicyklisk forbindelse og anvendelse deraf til inhibering af suv39h2
CN113387946B (zh) * 2021-05-17 2023-08-01 衡阳师范学院 一种超声辅助多组分合成2-苯基-3-芳胺甲基咪唑并吡啶衍生物的方法
EP4265248A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701780A (en) 1970-09-18 1972-10-31 Merck & Co Inc Imidazo(1,2-a)pyridines
JPS5341678B2 (es) 1974-03-22 1978-11-06
CH590862A5 (en) 1974-02-26 1977-08-31 Ciba Geigy Ag Isothiocyanato-substd. (2)-phenyl-imidazo (1,2-a)-pyridines prodn. - from corresp. amine and thiocarbonic acid derivs., useful as anthelmintics
JPS514194A (en) 1974-06-28 1976-01-14 Yoshitomi Pharmaceutical Imidazopirijinjudotaino seiho
JPS51125095A (en) 1974-07-23 1976-11-01 Yoshitomi Pharmaceut Ind Ltd A process for rreparing alcohol derivatives.
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
FR2525601A1 (fr) 1982-04-21 1983-10-28 Synthelabo Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2525602A1 (fr) 1982-04-21 1983-10-28 Synthelabo Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2568880B1 (fr) 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
DE3446778A1 (de) 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
FR2581646B1 (fr) 1985-05-07 1987-09-18 Synthelabo Derives d'imidazopyridine, leur preparation et leur application en therapeutique
ATE62687T1 (de) 1986-01-22 1991-05-15 Synthelabo Acylaminomethylimidazo(1,2-a>pyrimidinderivate, ihre herstellung und therapeutische verwendung.
FR2600650B1 (fr) 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
FR2606410B1 (fr) 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
WO1991019497A1 (en) 1990-06-12 1991-12-26 Smithkline Beecham Corporation Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
IN179790B (es) * 1992-02-10 1997-12-06 Council Scient Ind Res
IN179788B (es) * 1992-02-10 1997-12-06 Council Scient Ind Res
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
JPH11116481A (ja) 1997-10-06 1999-04-27 Sumitomo Pharmaceut Co Ltd スタット６活性化阻害剤
ES2151834B1 (es) 1998-08-06 2001-08-16 Sint Quimica Sa Procedimiento para preparar n,n,6-trimetil-2-(4-metilfenil)-imidazo-(1,2-a)-piridina-3-acetamida y sus sales.
WO2001074815A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives

Also Published As

Publication number Publication date
CA2439291C (en) 2008-01-08
PT1381363E (pt) 2005-04-29
US20030212096A1 (en) 2003-11-13
BR0208387A (pt) 2004-06-15
CN1529597A (zh) 2004-09-15
US6861437B2 (en) 2005-03-01
WO2002092086A1 (en) 2002-11-21
KR20030083013A (ko) 2003-10-23
US20040180921A1 (en) 2004-09-16
AR062387A2 (es) 2008-11-05
MXPA03008525A (es) 2003-12-08
US6596731B2 (en) 2003-07-22
US6916826B2 (en) 2005-07-12
DE60202200D1 (de) 2005-01-13
EP1381363A1 (en) 2004-01-21
KR100557847B1 (ko) 2006-03-10
US20020188128A1 (en) 2002-12-12
ZA200306341B (en) 2004-11-15
AU2002312768B2 (en) 2007-06-21
DE60202200T2 (de) 2005-12-15
JP2004525192A (ja) 2004-08-19
ES2232756T3 (es) 2005-06-01
EP1381363B1 (en) 2004-12-08
JP4088162B2 (ja) 2008-05-21
ATE284214T1 (de) 2004-12-15
CA2439291A1 (en) 2002-11-21
DK1381363T3 (da) 2005-04-18

Similar Documents

Publication Publication Date Title
AR037488A1 (es) El uso de un compuesto derivado de imidazo (1,2-a) piridina, un compuesto derivado de imidazo (1,2-a) piridina, y un medicamento que contiene dicho compuesto.
AR038047A1 (es) Agentes terapeuticos
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
CA2360003A1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
BR9500996A (pt) Derivado de difenila,agente terapêutico,processo para a preparação de um derivado de difenila,derivado de fenilpiperazina,composição farmacológica e métodos para fazer um medicamento e para tratar ou melhorar uma doença
NO960380D0 (no) Middel til behandling av neurosykdommer
AR043501A1 (es) Derivados de imidazol-4-il-etinil-piridina
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
AR051290A1 (es) Derivados de hidantoina sustituidas
IS6459A (is) Arýl sambrædd azapólýsýklísk efnasambönd
UY28374A1 (es) Agentes terapéuticos
HUP0101281A2 (hu) Glicin transzport inhibitor hatású difenil-piperidin-butánamid-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
AR050297A1 (es) Hidantoinas sustituidas
BRPI0409686A (pt) derivados de aza espiro alcano como inibidores de metaloproteases
AR047922A1 (es) Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos
ES2164924T3 (es) Antibioticos de cefalosporina.
RU2719599C2 (ru) Соединения 6, 7-дигидро-5H-пиразоло[5,1-b][1,3]оксазин-2-карбоксамида
AR050956A1 (es) Derivados de bencimidazol; sintesis de los mismos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por ligandos del receptor cb1.
AU2015239696B2 (en) Halogenated quinazolin-THF-amines as PDE1 inhibitors
NZ234533A (en) Isoquinoline derivatives, preparation and pharmaceutical compositions thereof
JP2021506806A (ja) 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
PE20040782A1 (es) DERIVADOS DE [6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-SULFONILAMINO]-PROPIONAMIDA

Legal Events

Date Code Title Description
FG Grant, registration